Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067499) BIOMARKER SIGNATURE FOR PREDICTING TUMOR RESPONSE TO ANTI-CD200 THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067499 International Application No.: PCT/US2018/052792
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
G01N 33/574 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
ALEXION PHARMACEUTICALS, INC. [US/US]; 121 Seaport Boulevard Boston, MA 02210, US
Inventors:
JI, Rui-ru; US
HAMILTON, Mark; US
BARR, Sharon; US
Agent:
REMILLARD, Jane, E.; US
BRULEY, Kenneth, C.; US
DIGIORGIO, Jeanne, M.; US
CANNING, Kevin, J.; US
DUKES, Mark, C.; US
Priority Data:
62/564,05227.09.2017US
62/578,64330.10.2017US
Title (EN) BIOMARKER SIGNATURE FOR PREDICTING TUMOR RESPONSE TO ANTI-CD200 THERAPY
(FR) SIGNATURE DE BIOMARQUEUR POUR LA PRÉDICTION D'UNE RÉPONSE TUMORALE VIS-À-VIS D'UNE THÉRAPIE ANTI-CD200
Abstract:
(EN) Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor. Also provided are methods for monitoring responsiveness of a patient having cancer to treatment with a CD200 inhibitor, the method comprising: determining expression levels of CD200R1 and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) in a biological sample from the patient, wherein increased expression levels of CD200R1 and the one or more biomarkers, as compared to expression levels in a biological sample of the same type obtained from the subject prior to treatment with the CD200 inhibitor, indicates that the subject is responsive to treatment with the CD200 inhibitor.
(FR) La présente invention concerne des méthodes de traitement du cancer chez un patient qui a été déterminé comme ayant une expression positive du récepteur CD200 (CD200R1) et un ou plusieurs biomarqueurs (à savoir ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163 et/ou CD14) par administration au patient d'un inhibiteur de CD200. L'invention concerne également des procédés de surveillance de la sensibilité d'un patient ayant un cancer vis-à-vis d'un traitement par un inhibiteur de CD200, le procédé comprenant: la détermination de taux d'expression de CD200R1 et d'un ou de plusieurs biomarqueurs (à savoir ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163 et/ou CD14) dans un échantillon biologique provenant du patient, où des taux d'expression accrus de CD200R1 et du ou des biomarqueurs, par comparaison avec des taux d'expression dans un échantillon biologique du même type obtenu à partir du sujet avant le traitement par l'inhibiteur de CD200, indique que le sujet est sensible au traitement par l'inhibiteur de CD200.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)